No Data
Investors Ignore Increasing Losses at Xiangxue PharmaceuticalLtd (SZSE:300147) as Stock Jumps 5.0% This Past Week
Xiangxue Pharmaceutical (300147.SZ): TAEST16001 injection is currently in Phase II clinical stage.
Gelonghui November 6th | xiangxue pharmaceutical (300147.SZ) stated on the investor interaction platform that TAEST16001 injection is currently in Phase II clinical stage. The progress of research and development will be disclosed to the public in the form of announcements based on clinical situations combined with information disclosure rules.
Revenues Not Telling The Story For Xiangxue Pharmaceutical Co.,Ltd. (SZSE:300147) After Shares Rise 101%
Xiangxue Pharmaceuticals: Report for the third quarter of 2024
Xiangxue Pharmaceutical (300147.SZ): a net loss of 0.218 billion yuan in the first three quarters.
GeLongHui October 25th | Xiangxue Pharmaceutical (300147.SZ) released the third quarter report for 2024, with the company achieving a revenue of 1.534 billion yuan in the first three quarters, a decrease of 11.26% year-on-year; net income attributable to shareholders of the listed company was -0.218 billion yuan; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -0.205 billion yuan; basic earnings per share -0.3300 yuan.
Does Xiangxue PharmaceuticalLtd (SZSE:300147) Have A Healthy Balance Sheet?
Xiangxue Pharmaceutical Co.,Ltd.'s (SZSE:300147) 29% Dip In Price Shows Sentiment Is Matching Revenues
